ArticleJournal of immunology (Baltimore, Md. : 1950)2014
Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation.Frontiers in immunology · 2021Pooled it
- TIM-3 rs1036199 polymorphism increases susceptibility to autoimmune diseases: evidence based on 4200 subjects.Bioscience reports · 2018Pooled it
- Lnc-TIM3 promotes acute lymphoblastic leukemia progression through miR-5094-mediated regulation of TIM3.Translational cancer research · 2026Article
- Circulating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer.iScience · 2026Article
- TIM-3, a potential target for sepsis therapy.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Review
- TIM-3 in Cardiovascular Disease.Current heart failure reports · 2026Review
- Unraveling Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities: Pathway Insights, Mechanisms, and Emerging Therapeutic Targets.Reviews in cardiovascular medicine · 2026Review
- CD226 identifies effector CD8Cell reports · 2025Article
- The role of Tim-3+T cell subsets in the peripheral blood of patients with COVID-19 and diabetes.iScience · 2025Article
- A microRNA-regulated transcriptional state defines intratumoral CD8Cell reports · 2025Article
- Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal transduction and targeted therapy · 2024Review
- Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis.Brain : a journal of neurology · 2024Article
- Tim-3 Is Not Required for Establishment of CD8+ T Cell Memory to Lymphocytic Choriomeningitis Virus.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma.World journal of urology · 2024Article
- The role of TIM-3 in sepsis: a promising target for immunotherapy?Frontiers in immunology · 2024Review
- Influence of Microbiota on Tumor Immunotherapy.International journal of biological sciences · 2024Review
- Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice.Biomedicines · 2023Review
- Characterization of antigen-specific CD8+ memory T cell subsets in peripheral blood of patients with multiple sclerosis.Frontiers in immunology · 2023Article
- Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8Molecular therapy. Methods & clinical development · 2022Article
- Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures.Journal of clinical laboratory analysis · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
T cell Ig and mucin domain (Tim) 3 is a surface molecule expressed throughout the immune system that can mediate both stimulatory and inhibitory effects. Previous studies have provided evidence that Tim-3 functions to enforce CD8 T cell exhaustion, a dysfunctional state associated with chronic stimulation. In contrast, the role of Tim-3 in the regulation of CD8 T cell responses to acute and transient stimulation remains undefined. To address this knowledge gap, we examined how Tim-3 affects CD8 T cell responses to acute Listeria monocytogenes infection. Analysis of wild-type (WT) mice infected with L. monocytogenes revealed that Tim-3 was transiently expressed by activated CD8 T cells and was associated primarily with acquisition of an effector phenotype. Comparison of responses to L. monocytogenes by WT and Tim-3 knockout (KO) mice showed that the absence of Tim-3 significantly reduced the magnitudes of both primary and secondary CD8 T cell responses, which correlated with decreased IFN-γ production and degranulation by Tim-3 KO cells stimulated with peptide Ag ex vivo. To address the T cell-intrinsic role of Tim-3, we analyzed responses to L. monocytogenes infection by WT and Tim-3 KO TCR-transgenic CD8 T cells following adoptive transfer into a shared WT host. In this setting, the accumulation of CD8 T cells and the generation of cytokine-producing cells were significantly reduced by the lack of Tim-3, demonstrating that this molecule has a direct effect on CD8 T cell function. Combined, our results suggest that Tim-3 can mediate a stimulatory effect on CD8 T cell responses to an acute infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.